[Form 4] ANI Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Ori Gutwerg, listed as SVP, Generics at ANI Pharmaceuticals (ANIP), reported a sale of 5,873 shares of ANI common stock on 08/12/2025. The shares were sold in multiple trades at prices ranging from $86.50 to $86.79, with a disclosed weighted average sale price of $86.53. After the transactions, the reporting person beneficially owned 84,024 shares, reported as direct ownership. The Form 4 was signed by an attorney-in-fact for the reporting person.

Positive

• Transparent disclosure of trade details including weighted average price and price range
• Post-sale ownership disclosed, showing continued direct stake of 84,024 shares

Negative

• Insider sale of 5,873 shares was executed, which reduces the reporting officer's holdings

Insights

Securities Analyst

TL;DR: A routine insider sale was reported; transaction details are transparent and show modest shares sold relative to total holdings.

The Form 4 documents a direct sale by an executive officer of 5,873 shares at a weighted average price of $86.53, executed in multiple trades priced between $86.50 and $86.79. The post-transaction beneficial ownership remains at 84,024 shares, indicating the sale reduced but did not eliminate the officer's stake. This filing provides clear execution prices and volume, which supports market transparency. The disclosure does not include any derivative activity or additional changes to ownership structure.

Corporate Governance Expert

TL;DR: Filing is a standard Section 16 disclosure documenting an open-market sale; no governance red flags in the report itself.

The report identifies the reporting person as an officer (SVP, Generics) and shows a straightforward disposition of common stock through multiple trades, with a weighted average sale price disclosed and direct ownership remaining significant. The Form 4 is signed by an attorney-in-fact, which is a common execution method. There are no indications in this filing of stock-based compensation exercises, grants, or transfers to related parties that would raise governance concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gutwerg Ori

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, GENERICS

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		S		5,873	D	$86.53(1)	84,024	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold in multiple trades at prices ranging from $86.50 to $86.79. The price reported above reflects the weighted average sales price.

Remarks:

	/s/ Ori Gutwerg, by attorney-in-fact Meredith W. Cook	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Ori Gutwerg report on the ANIP Form 4?

The report discloses a sale of 5,873 shares of ANI Pharmaceuticals common stock executed on 08/12/2025.

At what price were the ANIP shares sold in this Form 4?

Shares were sold in multiple trades at prices ranging from $86.50 to $86.79, with a weighted average sale price of $86.53.

How many ANIP shares does the reporting person own after the sale?

After the reported transactions, the reporting person beneficially owned 84,024 shares, reported as direct ownership.

What is the reporting person’s role at ANI Pharmaceuticals?

The Form 4 identifies the reporting person as SVP, Generics and an officer of ANI Pharmaceuticals.

Does the Form 4 show any derivative transactions for ANIP by the reporting person?

No. Table II for derivative securities shows no reported transactions or holdings in this filing.